J&J Talc MDL: Proposed $5.5B Mass Tort

The largest active US mass tort: roughly 68,400 federal claims that J&J’s talc-based baby powder causes ovarian cancer and mesothelioma, back in the tort system after courts rejected the company’s third ‘Texas Two-Step’ bankruptcy and its ~$9B plan. In July 2026 the MDL court ordered plaintiffs to show cause why their claims should not be dismissed after they withdrew key causation experts, and J&J proposed a $5.5B global settlement contingent on 95% participation.

LATEST DEVELOPMENT · JUL 27, 2026

On July 22, 2026, the MDL court ordered nearly 70,000 plaintiffs to show cause why their claims should not be dismissed after plaintiffs withdrew two key specific-causation experts. Days later, on July 27, 2026, J&J announced a proposed $5.5B global settlement covering the roughly 76,000 remaining ovarian cancer claims in federal and state courts per J&J’s securities filing (press reports put the figure at about 69,000), contingent on at least 95% of claimants agreeing to participate. The deal does not cover UK claims or mesothelioma cases.

BACKGROUND

Plaintiffs allege that Johnson’s Baby Powder and Shower to Shower were contaminated with asbestos and cause ovarian cancer and mesothelioma, and that J&J concealed the risk for decades. Federal ovarian cancer cases were consolidated as MDL 2738 in New Jersey in October 2016. State juries delivered headline verdicts, most famously $4.69B to 22 women in Ingham (2018), cut to $2.12B and left standing by the Supreme Court in 2021, and J&J pulled talc-based powder from North America in 2020 and worldwide by 2023. J&J then tried three times to resolve the litigation through the ‘Texas Two-Step’: subsidiary LTL Management’s 2021 and 2023 Chapter 11 filings were dismissed for lack of financial distress, and Red River Talc’s third filing, carrying a roughly $9B plan for 90,000+ ovarian claims, was rejected on 31 March 2025 by Judge Christopher Lopez over solicitation and voting defects. J&J declined to appeal, withdrew the offer, and says it will litigate every case.

The MDL has fully reactivated and keeps growing: 68,435 pending cases as of July 2026 (up 406 in a month), the largest active MDL in the federal system. In January 2026, court-appointed special master Freda Wolfson, the MDL’s former presiding judge, issued a 658-page report on renewed Daubert motions recommending that plaintiffs’ general-causation experts be allowed to testify that genital talc use is associated with ovarian cancer. J&J’s objections are before Judge Michael Shipp. Trial results swing wildly, a Baltimore jury awarded $1.56B to a single mesothelioma plaintiff in December 2025 while J&J has won defense verdicts elsewhere, and the litigation then turned abruptly. After plaintiffs withdrew their two specific-causation experts from the bellwether cases following a May 2026 evidentiary hearing, Magistrate Judge Rukhsanah L. Singh on July 22, 2026 ordered plaintiffs to show cause why the roughly 69,000 remaining MDL claims should not be dismissed for lack of admissible specific-causation evidence, and Judge Shipp heard the steering committee on its path forward on August 3. Five days after the show-cause order, on July 27, J&J announced a proposed $5.5B resolution of the remaining ovarian talc claims in federal and state courts, conditioned on participation by at least 95% of claimants, with a first payment of up to $3B in 2027.

TIMELINE

JUL 27, 2026SETTLEMENT

J&J announces proposed $5.5B global talc settlement

J&J announced a proposed comprehensive resolution of remaining ovarian cancer talc litigation for an estimated $5.5B, covering about 69,000 claims (99.75% of remaining claims) in federal MDL and state courts, contingent on at least 95% of claimants participating. J&J expects to pay $3B in 2027 with further payments in 2028. The deal excludes UK claims and mesothelioma cases and does not cap total payout.

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation J&J reaches sweeping talc deal that could end decade of litigation Johnson & Johnson offers $5.5bn to settle talc cancer lawsuits
JUL 22, 2026JUDGMENT

MDL court orders ~70,000 plaintiffs to show cause on specific causation

U.S. Magistrate Judge Rukhsanah L. Singh (MDL 2738, D.N.J.) granted J&J’s motion for an order to show cause why the remaining pending ovarian cancer claims should not be dismissed, after plaintiffs’ counsel withdrew their two specific-causation experts, Dr. Daniel Clarke-Pearson and Dr. Judith Wolf, from the bellwether cases following a May 2026 evidentiary hearing.

Johnson & Johnson Wins Big: Federal Judge Orders Nearly 70,000 Talc Claimants to Show Why They Shouldn't be Dismissed Talcum Powder MDL Court Orders All Plaintiffs to Show Cause on Specific Causation
JAN 2026PROCEDURAL

Special master recommends admitting plaintiffs’ causation experts

Retired Judge Freda Wolfson’s 658-page report found plaintiffs’ experts reliably showed a statistically significant association between genital talc use and ovarian cancer. J&J’s objections are before Judge Shipp.

Court-Appointed Expert’s Report Threatens J&J Talc Defense
DEC 22, 2025JUDGMENT

Baltimore jury awards $1.56B in Craft mesothelioma case

About $60M compensatory plus $1.5B punitive damages ($1B against J&J, $500M against Pecos River Talc), the largest single-plaintiff talc verdict. J&J is appealing.

J&J Talc Jury Awards $1.56 Billion to Asbestos Cancer Victim
MAR 31, 2025JUDGMENT

Bankruptcy court rejects the plan. J&J returns to the tort system

Judge Christopher Lopez found the solicitation and voting process defective and refused nonconsensual third-party releases. J&J said it would not appeal and withdrew its settlement offer.

What the Collapse of J&J’s Third Talc Bankruptcy Means
SEP 20, 2024OTHER

Red River Talc files the third bankruptcy with a ~$9B plan

The prepackaged Texas Chapter 11 claimed support from over 75% of some 90,000+ ovarian claimants.
JAN 30, 2023JUDGMENT

Third Circuit dismisses the first talc bankruptcy

The court held LTL was not in financial distress. A second LTL filing with an $8.9B proposal was dismissed in July 2023 on the same ground.
OCT 14, 2021OTHER

LTL Management files the first ‘Texas Two-Step’ bankruptcy

J&J moved its talc liabilities into a new subsidiary via a Texas divisional merger and put it into Chapter 11 to force a global resolution.
JUL 12, 2018JUDGMENT

Ingham jury awards $4.69B to 22 women

The St. Louis verdict was later reduced to $2.12B on appeal. The US Supreme Court declined review in June 2021.
OCT 4, 2016PROCEDURAL

JPML consolidates federal talc claims as MDL 2738 in New Jersey

EXPERIMENTAL AI FORECAST

HOW IT IS MADE →

Predicted outcome: Settlement
Model-assigned probability: about 70%
Timeframe: mid-2027 to 2028
Model confidence: medium

The most likely ending is a consummated global settlement of the ovarian claims at or near the announced $5.5 billion, roughly 70 percent likely, with participation locked in during 2027 and the first tranche of up to $3 billion paid that year and the balance in 2028. The mechanism is an opt-in inventory deal administered outside bankruptcy, averaging on the order of $70,000 to $90,000 per claim gross before fees, with tiered values that pay confirmed ovarian cancer claimants far more than unsupported registry filings. The single strongest driver is leverage timing: J&J made the offer five days after Magistrate Judge Singh ordered nearly 70,000 plaintiffs to show cause on specific causation, a posture that converts a large fraction of the inventory into claims worth little if the ruling goes against plaintiffs, so the plaintiffs’ bar has strong reason to bank cash now. The 95 percent condition is the main execution risk, but thresholds like this are routinely met once lead firms with the largest inventories sign, and J&J retains the option to waive or lower it rather than walk from a deal it has already accrued for. The leading alternative, roughly 20 percent, is that the deal collapses and Judge Shipp dismisses or guts the MDL inventory for lack of admissible specific-causation evidence, a respondent win that would still leave state court cases and appeals alive. Note that Wolfson’s January 2026 special master report is a recommendation on general causation only, not a merits finding, and the $1.56 billion Craft mesothelioma verdict is on appeal and sits outside this settlement along with UK claims. Expect residual litigation to continue for years on mesothelioma and opt-outs even after the ovarian deal closes.

Show-cause order on specific causation collapsed plaintiffs’ leverage · J&J offer already announced and accrued; payments scheduled 2027-2028 · 95% participation threshold is waivable and usually met · Mass tort inventories overwhelmingly settle once lead firms sign · Bankruptcy route foreclosed, so open-tort resolution is the only exit

Generated automatically by claude-opus-5 on Sep 13, 2026 from this case’s record on this site, and published without editorial review. The probability is the model’s judgment, not a measured frequency; there is no established validation record for these forecasts. Not legal or investment advice. How the forecasts are made →